Table 3 Positive and negative agreement of the patient reported outcomes with the ACR responder criteria in the abatacept treatment group
Patient reported outcomeACR20 responderACR50 responderACR70 responder
Yes*No†Overall‡YesNoOverallYesNoOverall
Activity limitation756066925157964851
Fatigue697773846568906062
Sleep quality537062646464666262
SF-36 Physical functioning587467866972866465
SF-36 Role-physical558069747272836970
SF-36 Bodily pain737474876266905759
SF-36 General health418365517773557573
SF-36 Vitality627570786668836364
SF-36 Social functioning566963706465766162
SF-36 Role-emotional437058526765666767
SF-36 Mental health387861517571597372
SF-36 Physical component597970867174866668
SF-36 Mental component417359507067596968

  • *Positive agreements were expressed as the percentage of patients who were classified as ACR responders who achieved >20% improvement in a study outcome.

  • †Negative agreements were expressed as the percentage of patients who were classified as ACR non-responders who had <20% improvement in a study outcome.

  • ‡Overall: overall agreements were either positive or negative agreements.

  • ACR20/ACR50/ACR70, >20%/50%/70% improvement in rheumatoid arthritis signs and symptoms defined by American College of Rheumatology criteria; SF-36, short form 36 item health survey.